To join this case, fill out the form below
By clicking on the Submit button below, I acknowledge that I have read the Retainer Agreement and agree to retain WeissLaw LLP to file an action against the Company in connection with this matter. WeissLaw LLP will prosecute the action on a contingent fee basis and will advance all costs and expenses.
By clicking on the Submit button below, I acknowledge that I have read the Derivative Retention Letter and agree to retain WeissLaw LLP to file an action against the Company in connection with this matter. WeissLaw LLP will prosecute the action on a contingent fee basis and will advance all costs and expenses.
A signed Retainer Agreement will be sent to your email shortly.
Oops! Something went wrong while submitting the form.

Vallon Pharmaceuticals, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Vallon Pharmaceuticals, Inc. (“Vallon” or the “Company”) (NASDAQ: VLON), in connection with the proposed merger of the Company with GRI Bio, Inc. (“GRI Bio”).  Under the merger agreement, Vallon will acquire 100% of the outstanding equity interests of GRI Bio, by means of reverse triangular merger of a wholly owned subsidiary of Vallon with and into GRI Bio, with GRI Bio surviving as a wholly owned subsidiary of Vallon.  Upon completion of the transaction, Vallon shareholders are expected to only own approximately 17% of the combined company, while GRI Bio shareholders are expected to own approximately 83%.

Weiss Law is investigating whether (i) Vallon’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the merger consideration adequately compensates Vallon’s shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.